# Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer

> **NCT05757336** · PHASE2 · RECRUITING · sponsor: **Lu Wang, MD, PhD** · enrollment: 50 (estimated)

## Conditions studied

- Gallbladder Cancer
- Initially Unresectable
- the First Line Treatment

## Interventions

- **DRUG:** Combination of Gemcitabine, Nab-paclitaxel, Sintilimab and Bevacizumab

## Key facts

- **NCT ID:** NCT05757336
- **Lead sponsor:** Lu Wang, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12-22
- **Primary completion:** 2024-12-22
- **Final completion:** 2026-12-22
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2023-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05757336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05757336, "Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT05757336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*